FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313160172> ?p ?o ?g. }

• W4313160172 endingPage "308" @default.
• W4313160172 startingPage "297" @default.
• W4313160172 abstract "Background: germline mutations in the BRCA1 and BRCA2 genes are associated with a high risk of developing cancer of various localizations. Currently, the determination of BRCA status in such patients is important for choosing surgical tactics and determining indications for the administration of multiple chemotherapy drugs. Aim: to evaluate the results of mass genetic screening for mutations in the BRCA1 and BRCA2 genes in patients with various types of malignant neoplasms (MN). Patients and Methods: the results of genetic screening of 5043 patients who are reviewed in the study. The patients had the following diagnoses: breast cancer (BC, n=4216), ovarian cancer (OC, n=481), multiple primary malignant neoplasms (n=174), pancreatic cancer (n=96) and prostate cancer (n=75). Real-time PCR-based genetic testing for eight recurrent BRCA1/2 gene mutations specific for the Russian population was performed for all patients. The study of the entire coding sequence of the BRCA1/2 genes was carried out in 655 patients with negative screening results for mutations using high-resolution melting curve analysis, Sanger sequencing, and massively parallel sequencing. Results and Discussion: among 5043 cancer patients, the total frequency of BRCA mutations was 8%. In patients with BC the recurrent variants accounted for 6.7%, bilateral BC — 13.5%, OC — 17%, multiple primary malignant neoplasms (MPMN) — 13.1%, pancreatic cancer — 3.1%, while in patients with prostate cancer no mutations were found. The frequency of the c.5266dup mutation in the BRCA1 gene was 5.63%. Forty nine patients (0.97%) were carriers of another mutation — p.C61G, which is specific for the Slavic populations. Other variants were found much less frequently (0.1–0.38%). Thus, screening for common mutations helped to determine the prevalence of each of the variants and proved a high frequency of c.5266dup and p.C61G mutations. The analysis of the coding sequence of the BRCA1/2 genes in 655 patients revealed pathogenic mutations (class 5) in 13% of cases. The prevalence of rare variants in patients with BC was 11.1%, bilateral BC — 26.5%, OC — 14.9%, МPМN — 31%, pancreatic cancer — 2.3%, and prostate cancer — 2.5%. In the BRCA1 gene, 41 unique clinically significant mutations were found, and four of them were repeated in unrelated patients. In the BRCA2 gene, 29 unique clinically significant mutations were found, five of which were repeated. Moreover, 19 missense mutations were detected which, according to the databases, were categorized as variants with unknown clinical significance (class 3). They were analyzed using seven pathogenicity prediction algorithms. As a result, five mutations were interpreted by the most algorithms as likely pathogenic or pathogenic (class 4/5), five mutations were re-assessed as variants with unknown significance, and nine variants were identified as clinically insignificant. Conclusion: thus, the Russian population is characterized by the presence of multiple recurrent mutations, while in patients with different cancer types the prevalence of c.5266dup and p.C61G is significantly higher than the prevalence of other variants. Analysis of recurrent variants in the BRCA1/2 genes enables identification of approx. 80% of carriers of the pathogenic mutations. The use of the panel kit which includes such variants is considered as an inexpensive and sensitive algorithm for the first-step screening of the BRCA1/2 genes. A follow-on investigation of all coding gene regions (sequencing) is feasible for the studied patient groups and can significantly increase the detectability of pathogenic mutations in the BRCA1/2 genes. KEYWORDS: BRCA1 mutations, BRCA2 mutations, breast cancer, ovarian cancer, malignant neoplasms. FOR CITATION: Stroganova A.M., Pospekhova N.I., Golovina D.A. et al. Review of the results of mass screening for the BRCA1/2 gene mutations in patients with different types of malignant neoplasms. Russian Medical Inquiry. 2022;6(6):297–308 (in Russ.). DOI: 10.32364/2587-6821- 2022-6-6-297-308." @default.
• W4313160172 created "2023-01-06" @default.
• W4313160172 creator A5017838064 @default.
• W4313160172 creator A5035904947 @default.
• W4313160172 creator A5041690269 @default.
• W4313160172 creator A5070155285 @default.
• W4313160172 creator A5080847408 @default.
• W4313160172 creator A5091039253 @default.
• W4313160172 date "2022-01-01" @default.
• W4313160172 modified "2023-09-30" @default.
• W4313160172 title "Review of the results of mass screening for the BRCA1/2 gene mutations in patients with different types of malignant neoplasms" @default.
• W4313160172 doi "https://doi.org/10.32364/2587-6821-2022-6-6-297-308" @default.
• W4313160172 hasPublicationYear "2022" @default.
• W4313160172 type Work @default.
• W4313160172 citedByCount "0" @default.
• W4313160172 crossrefType "journal-article" @default.
• W4313160172 hasAuthorship W4313160172A5017838064 @default.
• W4313160172 hasAuthorship W4313160172A5035904947 @default.
• W4313160172 hasAuthorship W4313160172A5041690269 @default.
• W4313160172 hasAuthorship W4313160172A5070155285 @default.
• W4313160172 hasAuthorship W4313160172A5080847408 @default.
• W4313160172 hasAuthorship W4313160172A5091039253 @default.
• W4313160172 hasBestOaLocation W43131601721 @default.
• W4313160172 hasConcept C104317684 @default.
• W4313160172 hasConcept C121608353 @default.
• W4313160172 hasConcept C126322002 @default.
• W4313160172 hasConcept C13514818 @default.
• W4313160172 hasConcept C143998085 @default.
• W4313160172 hasConcept C2780192828 @default.
• W4313160172 hasConcept C2780210213 @default.
• W4313160172 hasConcept C2780427987 @default.
• W4313160172 hasConcept C2908647359 @default.
• W4313160172 hasConcept C501734568 @default.
• W4313160172 hasConcept C502942594 @default.
• W4313160172 hasConcept C530470458 @default.
• W4313160172 hasConcept C54355233 @default.
• W4313160172 hasConcept C71924100 @default.
• W4313160172 hasConcept C76818968 @default.
• W4313160172 hasConcept C86803240 @default.
• W4313160172 hasConcept C99454951 @default.
• W4313160172 hasConceptScore W4313160172C104317684 @default.
• W4313160172 hasConceptScore W4313160172C121608353 @default.
• W4313160172 hasConceptScore W4313160172C126322002 @default.
• W4313160172 hasConceptScore W4313160172C13514818 @default.
• W4313160172 hasConceptScore W4313160172C143998085 @default.
• W4313160172 hasConceptScore W4313160172C2780192828 @default.
• W4313160172 hasConceptScore W4313160172C2780210213 @default.
• W4313160172 hasConceptScore W4313160172C2780427987 @default.
• W4313160172 hasConceptScore W4313160172C2908647359 @default.
• W4313160172 hasConceptScore W4313160172C501734568 @default.
• W4313160172 hasConceptScore W4313160172C502942594 @default.
• W4313160172 hasConceptScore W4313160172C530470458 @default.
• W4313160172 hasConceptScore W4313160172C54355233 @default.
• W4313160172 hasConceptScore W4313160172C71924100 @default.
• W4313160172 hasConceptScore W4313160172C76818968 @default.
• W4313160172 hasConceptScore W4313160172C86803240 @default.
• W4313160172 hasConceptScore W4313160172C99454951 @default.
• W4313160172 hasIssue "6" @default.
• W4313160172 hasLocation W43131601721 @default.
• W4313160172 hasOpenAccess W4313160172 @default.
• W4313160172 hasPrimaryLocation W43131601721 @default.
• W4313160172 hasRelatedWork W2023425329 @default.
• W4313160172 hasRelatedWork W2043890160 @default.
• W4313160172 hasRelatedWork W2167863344 @default.
• W4313160172 hasRelatedWork W2764038087 @default.
• W4313160172 hasRelatedWork W2809002819 @default.
• W4313160172 hasRelatedWork W2895367033 @default.
• W4313160172 hasRelatedWork W2967331293 @default.
• W4313160172 hasRelatedWork W3187221127 @default.
• W4313160172 hasRelatedWork W377899687 @default.
• W4313160172 hasRelatedWork W4239005280 @default.
• W4313160172 hasVolume "6" @default.
• W4313160172 isParatext "false" @default.
• W4313160172 isRetracted "false" @default.
• W4313160172 workType "article" @default.